IQE : Bullish and Bearish Analyst Opinions

Sentiment & Price 24 ideas • 2 voices • 2 sources
Sentiment Gauge
2
Bull
0
Bear
0
Watch
Bull 100% Bear 0%
Price & Sentiment
Loading chart...
Recent News Top Views
No recent news for IQE
No theses available
Feed
All Sources
YouTube
Twitter
Reddit
Substack
Insider
News
Loading...
All directions
▲ Long
▼ Short
◦ Others
Any score
LOW+
MED+
HIGH
07:58
Apr 13
Ride the parabolic momentum in IQE as major institutional funds like Point72 aggressively accumulate the available float at all-time highs.
IQE
MED
13:32
Apr 12
Buy IQE as the company pivots its asset base toward photonics and executes asset sales to deleverage its balance sheet, setting up a potential massive valuation re-rating.
IQE
HIGH
08:40
Apr 01
The stock offers a highly asymmetric risk/reward profile with 5-10x upside potential contingent on a successful restructuring and pivot toward InP AI segments.
IQE
MED
18:59
Mar 30
ParadisLabs AI/Semiconductor Analyst and Trader. 10+ yrs Portfolio Mana…
The semiconductor supply chain is facing significant downward pressure from multiple simultaneous negative forces.
IQE
10:03
Mar 27
The author is long on IQE due to its inherent value and a forward-looking conviction that the company will be acquired by either LITE or Landmark as part of a restructuring.
IQE
HIGH
15:14
Mar 20
The stock has significant upside potential (2.5x) contingent on a successful restructuring, which would unlock the value of its large asset base despite its current debt load.
IQE
MED
09:21
Mar 20
A long position in IQE is attractive due to latent capacity that can be repurposed, with a potential near-term catalyst from a debt restructuring or asset sale.
IQE
MED
22:17
Mar 14
The author believes IQE has significant upside potential if it can restructure its legacy business and debt, and pivot its existing capacity towards the AI photonics sector.
IQE
MED
22:14
Mar 14
The author believes IQE is significantly undervalued relative to peers and will re-rate higher as it restructures and focuses on its AI-related photonics capacity, a thesis now being publicly validated by the company's CTO.
IQE
MED
23:11
Mar 07
The stock is an early, high-risk investment with significant upside potential based on peer valuations, though this is conditional on a successful company restructuring.
IQE
MED
13:54
Mar 04
The stock is undervalued based on its core photonics business, a value that could be unlocked if the company sells its Taiwan division to deleverage its balance sheet.
IQE
MED
13:53
Mar 04
It’s ~41m euro gross debt, off the top of my head 10-14% share dilution + 24m gross debt. So yes $IQE debt. The main point was that if they sell their Taiwan business to clear that debt, their balance sheet looks clean and all the tractors + positioning in photonics supply chains far exceeds valuation. This was the personal reason why I took the trade but i wouldn’t recommend it since it’s generally risky for a lot of people.
IQE
22:08
Feb 27
The stock is a high-risk, high-reward long based on its potential to refactor capacity toward InP epiwafers, though this is balanced by significant debt, execution, and dilution risks.
IQE
MED
10:11
Feb 27
The author speculates that IQE is a potential M&A target for specific industry players, which could lead to a takeover premium.
IQE
MED
09:58
Feb 27
A successful sale of its Taiwan asset combined with a successful pivot to AI transceivers could lead to a significant stock rerating.
IQE
MED
09:43
Feb 27
The author argues that IQE, a leader in its semiconductor niche, is trading at a distressed valuation and possesses "hidden optionality" that the market is mispricing.
IQE
MED
06:50
Feb 27
The author is taking a long position in this epiwafer foundry as a higher-beta way to play the photonics theme, noting they have personally added it to risk-on portfolios.
IQE
MED
08:15
Feb 26
The author believes IQE is significantly undervalued at a $150M valuation compared to its closest peer, which is valued at $3.8B, despite being the largest epiwafer foundry in the world.
IQE
MED
21:28
Feb 25
This is a speculative long on IQE, betting that the company's strategic importance in the hyperscaler supply chain will ultimately outweigh its very weak balance sheet.
IQE
MED
15:47
Feb 25
IQE is significantly undervalued relative to peers and could experience a substantial re-rating if the company pivots to a pure-play business model.
IQE
MED
15:09
Feb 25
The author suggests a long position in IQE based on its low valuation relative to a Taiwanese peer and a potential catalyst from selling a legacy division to clear debt, which could lead to a significant re-rating.
IQE
MED
13:52
Feb 25
IQE is a potential value play that could re-rate significantly higher if it resolves its balance sheet issues, given its large production capacity relative to its small market cap.
IQE
MED
13:15
Feb 25
The author is flagging IQE as a potential winner based on their stated expertise in photonic supply chains, with an implied 3-month timeframe for the idea to play out.
IQE
MED
11:52
Feb 25
The author implies IQE is a key upstream supplier of epi-wafers in the high-growth photonics supply chain for Google's TPUs, positioning it for significant upside similar to a previous successful call on AXTI.
IQE
MED

About IQE Analyst Coverage

Buzzberg tracks IQE across 2 sources. 23 bullish vs 1 bearish calls from 2 analysts. Sentiment: predominantly bullish (92%). 24 total trade ideas tracked.